Medpace expert:

Thomas Todaro, MD, JD, FACC, Medpace Vice President, Medical Affairs.

Over the past several years a number of non-antiarrhythmic drugs have been withdrawn from the market, or have had their product labels revised due to the unexpected post-marketing reports of sudden cardiac deaths associated with a prolongation of the QT interval and the development of Torsade de Pointes (TdP). In this podcast, Dr. Todaro discusses:

•  An overview of thorough QT assessment and its role in early phase drug development for non-antiarrythmic drugs
• Factors to consider in drug development for this class of drug
• Regulatory updates and a forward look at early phase development for cardiac therapeutics
  

Want to learn more? Contact us.